Dementia and Alzheimer Disease

The director of the Weill Cornell Women’s Brain Initiative shared her clinical insights into how menopause affects women's brain health, emphasizing the importance of midlife prevention strategies for Alzheimer disease. [WATCH TIME: 10 minutes]

The associate professor of neurology at Georgetown University Medical Center talked about innovative treatments for dementia in movement disorders that target multiple mechanisms to effectively modify the disease. [WATCH TIME: 7 minutes]

The neurologist and assistant professor at Boston University Medical Center provided clarity on recent findings on a validation study demonstrating the low accuracy of the Boston criteria v2.0 in patients who are asympomatic or only have cognitive symptoms. [WATCH TIME: 7 minutes]

Neal K. Shah, CEO of CareYaya Health Technologies, discussed the groundbreaking potential of AI-powered music therapy in revolutionizing dementia care, offering personalized interventions that can improve quality of life.

Catch up on any of the neurology news headlines you may have missed over the course of June 2024, compiled all into one place by the NeurologyLive® team.

The associate professor of neurology at Georgetown University Medical Center talked about the potential of tyrosine kinase inhibitors in treating neurodegenerative diseases. [WATCH TIME: 7 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on headache and nerve decompression surgery.

ALX-001, a first-in-class compound, will be assessed in an additional cohort of patients with Alzheimer disease as the company continues to plan for phase 2 studies.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 5, 2024.

The approval of donanemab marks the third antiamyloid therapy to gain the FDA's greenlight, following the conditional approval of aducanumab in 2021, and lecanemab in 2023—although aducanumab no longer remains on market after it was removed earlier this year.

Here's some of what is coming soon to NeurologyLive® this week.

Vitrisiran demonstrated a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular events in both the overall population and those who received a monotherapy of vutrisiran without tafamidis.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy/Dravet syndrome.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 28, 2024.

The director of the Memory Disorders Program at Georgetown University talked about newly approved anti-amyloid antibodies that show significant promise in slowing Alzheimer disease progression. [WATCH TIME: 5 minutes]

The associate professor of neurology at Georgetown University Medical Center talked about disease-modifying therapies for movement disorder-related dementia that aim to address the underlying mechanisms of the disease. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending June 22, 2024. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Alzheimer disease/dementia.

The assistant professor at the University of South Florida provided perspective on the influence of circadian rhythm in neurocognitive health and the possibilities of screening for circadian rhythm issues for large-scale clinical trials. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 21, 2024.

Neal K. Shah, CEO of CareYaya Health Technologies, discussed how sleep apnea and cognitive decline may be interrelated and disproportionately affecting minoritized populations.

A statistically significant dose-response correlation was observed, indicating that greater lifestyle changes led to better cognitive and functional outcomes in Alzheimer's patients.

In recent news, Otsuka has discontinued the development of AVP-786 following results from phase 3 trial assessing the treatment in patients with agitation related to Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on narcolepsy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 14, 2024.

John Dunlop, PhD, the chief scientific officer at Aliada Therapeutics, discussed the MODEL platform and its potential impact on therapeutic delivery for neurological conditions.

The president and CEO at Alzheon talked about the recent discoveries made in understanding the pathology of Alzheimer disease and the development of innovative therapies to potentially set the stage for more effective care. [WATCH TIME: 12 minutes]